Angiogenesis

, Volume 13, Issue 1, pp 43–58

Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer

  • Jennifer Delli Carpini
  • Amer K. Karam
  • Leslie Montgomery
Article

Abstract

Tumor neovascularization is a complex process that plays a crucial role in the development of many different types of cancer. Vascular endothelial growth factor (VEGF) is a potent mitogen that is involved with mitogenesis, angiogenesis, endothelial survival, and the induction of hematopoiesis. By increasing vascular permeability in endothelial cells, it helps tumors recruit wound-healing proteins fibrin and fibrinogen from the plasma, suggesting that tumor formation is a process of abnormal wound healing dependent on the ability to generate a blood supply. The human female reproductive tract is highly dependent on VEGF for normal functions such as endometrial proliferation and development of the corpus luteum. The unique influence of female sex steroid hormones on the expression and activity of VEGF deems angiogenesis an important facet of the development of breast and ovarian cancer. Additionally, the up-regulation of VEGF by the E6 oncoprotein of the human papillomavirus suggests that VEGF plays an important role in the development of cervical cancer. Clinical trials have investigated the humanized monoclonal antibody bevacizumab as potential treatment for all three forms of cancer; the data show that in breast cancer, the use of bevacizumab may lengthen the disease-free survival for women with advanced breast cancer, but does not appear to change their overall survival. It may have a role as salvage chemotherapy for ovarian and cervical cancer, though further research is needed to establish it as a definitive form of treatment.

Keywords

Vascular endothelial growth factor VEGF Breast cancer Mitogen Ovarian cancer Cervical cancer 

References

  1. 1.
    Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77(7):527–543CrossRefPubMedGoogle Scholar
  2. 2.
    Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983–985CrossRefPubMedGoogle Scholar
  3. 3.
    Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133(2):275–288CrossRefPubMedGoogle Scholar
  4. 4.
    Schoppmann SF, Horvat R, Birner P (2002) Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncol Rep 9(3):455–460PubMedGoogle Scholar
  5. 5.
    Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ (eds) (2005) Cancer cell biology and angiogenesis: introduction, 16th edn. McGraw-Hill, New York Harrison’s Principles of Internal Medicine; No. 5Google Scholar
  6. 6.
    Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4–25CrossRefPubMedGoogle Scholar
  7. 7.
    Dvorak HF (1986) Tumors: wounds that do not heal. N Engl J Med 315(26):1650–1659PubMedCrossRefGoogle Scholar
  8. 8.
    Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM (1987) Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 57(6):673–686PubMedGoogle Scholar
  9. 9.
    Vincenti V, Cassano C, Rocchi M, Persico G (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93(8):1493–1495PubMedGoogle Scholar
  10. 10.
    Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266(18):11947–11954PubMedGoogle Scholar
  11. 11.
    Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5(12):1806–1814CrossRefPubMedGoogle Scholar
  12. 12.
    Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N (1996) The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271(13):7788–7795CrossRefPubMedGoogle Scholar
  13. 13.
    Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N (1992) Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89(1):244–253CrossRefPubMedGoogle Scholar
  14. 14.
    Jakeman LB, Armanini M, Phillips HS, Ferrara N (1993) Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 133(2):848–859CrossRefPubMedGoogle Scholar
  15. 15.
    Vaisman N, Gospodarowicz D, Neufeld G (1990) Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265(32):19461–19466PubMedGoogle Scholar
  16. 16.
    Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84(5):1470–1478CrossRefPubMedGoogle Scholar
  17. 17.
    de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255(5047):989–991CrossRefPubMedGoogle Scholar
  18. 18.
    Cunningham SA, Waxham MN, Arrate PM, Brock TA (1995) Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem 270(35):20254–20257CrossRefPubMedGoogle Scholar
  19. 19.
    Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269(43):26988–26995PubMedGoogle Scholar
  20. 20.
    Guo D, Jia Q, Song HY, Warren RS, Donner DB (1995) Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270(12):6729–6733CrossRefPubMedGoogle Scholar
  21. 21.
    Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226(2):324–328CrossRefPubMedGoogle Scholar
  22. 22.
    Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T (1996) Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77(6):1101–1106CrossRefPubMedGoogle Scholar
  23. 23.
    Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593–4599PubMedGoogle Scholar
  24. 24.
    Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T (1996) Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2(5):821–826PubMedGoogle Scholar
  25. 25.
    Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE (2000) Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60(11):2898–2905PubMedGoogle Scholar
  26. 26.
    Veronesi U, Galimberti V, Zurrida S, Merson M, Greco M, Luini A (1993) Prognostic significance of number and level of axillary nodal metastases in breast cancer. Breast 2:224–228CrossRefGoogle Scholar
  27. 27.
    Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):966–978PubMedGoogle Scholar
  28. 28.
    Toi M, Kashitani J, Tominaga T (1993) Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55(3):371–374CrossRefPubMedGoogle Scholar
  29. 29.
    Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84(24):1875–1887CrossRefPubMedGoogle Scholar
  30. 30.
    Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340(8828):1120–1124CrossRefPubMedGoogle Scholar
  31. 31.
    Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12(3):454–466PubMedGoogle Scholar
  32. 32.
    Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969PubMedGoogle Scholar
  33. 33.
    Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP (1996) Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56(9):2013–2016PubMedGoogle Scholar
  34. 34.
    Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF (2000) Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 92(6):486–492CrossRefPubMedGoogle Scholar
  35. 35.
    Osanai T, Wakita T, Gomi N, Takenaka S, Kakimoto M, Sugihara K (2003) Correlation among intratumoral blood flow in breast cancer, clinicopathological findings and Nottingham Prognostic Index. Jpn J Clin Oncol 33(1):14–16CrossRefPubMedGoogle Scholar
  36. 36.
    Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121–3128PubMedGoogle Scholar
  37. 37.
    Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2):139–147CrossRefPubMedGoogle Scholar
  38. 38.
    Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R (2000) Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18(7):1423–1431PubMedGoogle Scholar
  39. 39.
    Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61(14):5407–5414PubMedGoogle Scholar
  40. 40.
    Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10(5):1706–1716CrossRefPubMedGoogle Scholar
  41. 41.
    Kawai H, Li H, Chun P, Avraham S, Avraham HK (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21(50):7730–7739CrossRefPubMedGoogle Scholar
  42. 42.
    Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C, Perrot-Applanat M (2000) Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol 279(5):H2033–H2042PubMedGoogle Scholar
  43. 43.
    Ali SH, O’Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S, Dandona P (2000) Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 60(24):7094–7098PubMedGoogle Scholar
  44. 44.
    Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66(23):11207–11213CrossRefPubMedGoogle Scholar
  45. 45.
    Johns A, Freay AD, Fraser W, Korach KS, Rubanyi GM (1996) Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 137(10):4511–4513CrossRefPubMedGoogle Scholar
  46. 46.
    Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62(17):4977–4984PubMedGoogle Scholar
  47. 47.
    Fuckar D, Dekanic A, Stifter S, Mustac E, Krstulja M, Dobrila F, Jonjic N (2006) VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol 14(1):49–55CrossRefPubMedGoogle Scholar
  48. 48.
    Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ (2001) Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 7(11):3491–3494PubMedGoogle Scholar
  49. 49.
    Bando H (2007) Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer 14(2):163–173CrossRefPubMedGoogle Scholar
  50. 50.
    Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, Yu HJ, Nalcioglu O, Su MY (2009) Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without Bevacizumab. Ann Surg OncolGoogle Scholar
  51. 51.
    Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24(5):769–777CrossRefPubMedGoogle Scholar
  52. 52.
    Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M (2009) Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer DrugsGoogle Scholar
  53. 53.
    Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B (2009) Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg OncolGoogle Scholar
  54. 54.
    Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(5 Suppl 16):117–124CrossRefPubMedGoogle Scholar
  55. 55.
    Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12(10):3124–3129CrossRefPubMedGoogle Scholar
  56. 56.
    Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP (2008) VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 14(23):7871–7877CrossRefPubMedGoogle Scholar
  57. 57.
    Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676CrossRefPubMedGoogle Scholar
  58. 58.
    Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792–799CrossRefPubMedGoogle Scholar
  59. 59.
    Traina TA, Rugo HS, Dickler M (2007) Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21(2):303–319CrossRefPubMedGoogle Scholar
  60. 60.
    Torry DS, Holt VJ, Keenan JA, Harris G, Caudle MR, Torry RJ (1996) Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 66(1):72–80PubMedGoogle Scholar
  61. 61.
    Bausero P, Cavaille F, Meduri G, Freitas S, Perrot-Applanat M (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. Angiogenesis 2(2):167–182PubMedGoogle Scholar
  62. 62.
    Bassett DEL (1943) The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am J Anat 73:251–278CrossRefGoogle Scholar
  63. 63.
    Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4(3):336–340CrossRefPubMedGoogle Scholar
  64. 64.
    Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF (1995) Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 146(1):157–165PubMedGoogle Scholar
  65. 65.
    Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB (1996) Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 81(1):353–359CrossRefPubMedGoogle Scholar
  66. 66.
    Heer K, Kumar H, Speirs V, Greenman J, Drew PJ, Fox JN, Carleton PJ, Monson JR, Kerin MJ (1998) Vascular endothelial growth factor in premenopausal women—indicator of the best time for breast cancer surgery? Br J Cancer 78(9):1203–1207PubMedGoogle Scholar
  67. 67.
    Agrawal R, Conway GS, Sladkevicius P, Payne NN, Bekir J, Campbell S, Tan SL, Jacobs HS (1999) Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flow. Clin Endocrinol (Oxf) 50(1):101–106CrossRefGoogle Scholar
  68. 68.
    Chung HC, Rha SY, Ahn JB, Shim KY, Yoo NC, Kim JH, Roh JK, Lee KS, Min JS, Kim BS, Kim JJ (1998) Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. Int J Mol Med 2(4):465–470PubMedGoogle Scholar
  69. 69.
    Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E (1993) Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 91(5):2235–2243CrossRefPubMedGoogle Scholar
  70. 70.
    Cullinan-Bove K, Koos RD (1993) Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133(2):829–837CrossRefPubMedGoogle Scholar
  71. 71.
    Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP, Fountain SA, Boocock CA, Smith SK (1993) Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod 48(5):1120–1128CrossRefPubMedGoogle Scholar
  72. 72.
    Perrot-Applanat M, Ancelin M, Buteau-Lozano H, Meduri G, Bausero P (2000) Ovarian steroids in endometrial angiogenesis. Steroids 65(10–11):599–603CrossRefPubMedGoogle Scholar
  73. 73.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66CrossRefPubMedGoogle Scholar
  74. 74.
    Olson TA, Mohanraj D, Carson LF, Ramakrishnan S (1994) Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54(1):276–280PubMedGoogle Scholar
  75. 75.
    Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87(7):506–516CrossRefPubMedGoogle Scholar
  76. 76.
    Paley PJ, Goff BA, Gown AM, Greer BE, Sage EH (2000) Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 78(3 Pt 1):336–341CrossRefPubMedGoogle Scholar
  77. 77.
    Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T (1998) Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 83(12):2528–2533CrossRefPubMedGoogle Scholar
  78. 78.
    Hazelton D, Nicosia RF, Nicosia SV (1999) Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 5(4):823–829PubMedGoogle Scholar
  79. 79.
    Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ (1998) Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90(6):447–454CrossRefPubMedGoogle Scholar
  80. 80.
    Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80(1):98–106CrossRefPubMedGoogle Scholar
  81. 81.
    Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S (1997) Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121(2):169–175CrossRefPubMedGoogle Scholar
  82. 82.
    Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C (1998) Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92(3):360–363CrossRefPubMedGoogle Scholar
  83. 83.
    Obermair A, Tempfer C, Hefler L, Preyer O, Kaider A, Zeillinger R, Leodolter S, Kainz C (1998) Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br J Cancer 77(11):1870–1874PubMedGoogle Scholar
  84. 84.
    Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK (2002) Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 8(10):3193–3197PubMedGoogle Scholar
  85. 85.
    Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153(4):1249–1256PubMedGoogle Scholar
  86. 86.
    Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(33):5165–5171CrossRefPubMedGoogle Scholar
  87. 87.
    Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180–5186CrossRefPubMedGoogle Scholar
  88. 88.
    Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26(1):76–82CrossRefPubMedGoogle Scholar
  89. 89.
    Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110(1):49–55CrossRefPubMedGoogle Scholar
  90. 90.
    Han ES, Lin P, Wakabayashi M (2009) Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr Treat Options OncolGoogle Scholar
  91. 91.
    Han ES, Monk BJ (2007) Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 7(10):1339–1345CrossRefPubMedGoogle Scholar
  92. 92.
    Bosch FX, de Sanjose S (2003) Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J Natl Cancer Inst Monogr (31):3–13Google Scholar
  93. 93.
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244–265PubMedGoogle Scholar
  94. 94.
    Smith-McCune KK, Weidner N (1994) Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54(3):800–804PubMedGoogle Scholar
  95. 95.
    Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF (1995) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87(16):1237–1245CrossRefPubMedGoogle Scholar
  96. 96.
    Kodama J, Seki N, Tokumo K, Hongo A, Miyagi Y, Yoshinouchi M, Okuda H, Kudo T (1999) Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 35(3):485–489CrossRefPubMedGoogle Scholar
  97. 97.
    Tokumo K, Kodama J, Seki N, Nakanishi Y, Miyagi Y, Kamimura S, Yoshinouchi M, Okuda H, Kudo T (1998) Different angiogenic pathways in human cervical cancers. Gynecol Oncol 68(1):38–44CrossRefPubMedGoogle Scholar
  98. 98.
    Santin AD, Hermonat PL, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP (1999) Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstet Gynecol 94(1):78–82CrossRefPubMedGoogle Scholar
  99. 99.
    Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM (2000) Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83(5):620–625CrossRefPubMedGoogle Scholar
  100. 100.
    Cheng WF, Chen CA, Lee CN, Chen TM, Hsieh FJ, Hsieh CY (1999) Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 93(5 Pt 1):761–765CrossRefPubMedGoogle Scholar
  101. 101.
    Cheng WF, Chen CA, Lee CN, Wei LH, Hsieh FJ, Hsieh CY (2000) Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 96(5 Pt 1):721–726CrossRefPubMedGoogle Scholar
  102. 102.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19CrossRefPubMedGoogle Scholar
  103. 103.
    Smith-McCune K, Zhu YH, Hanahan D, Arbeit J (1997) Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 57(7):1294–1300PubMedGoogle Scholar
  104. 104.
    Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS (2000) Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19(40):4611–4620CrossRefPubMedGoogle Scholar
  105. 105.
    Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS (2006) Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103(2):489–493CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Jennifer Delli Carpini
    • 1
    • 2
  • Amer K. Karam
    • 1
  • Leslie Montgomery
    • 1
  1. 1.Breast Service, Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Breast SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations